Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
9 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to 60 Degrees Pharmaceuticals, Inc.’s names, not what it holds today.
Patents granted
9
9 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against none in 2024 and 2 in 2023
Applications published
18
1 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
60 DEGREES PHARMACEUTICALS LLC its own name
US, as the owner printed on each patent
17 published60 DEGREES PHARMACEUTICALS LLC its own name
named as the applicant on its applications, in US
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Aug 12, 2025 | 12,383,546 | Methods for the treatment and prevention of lung infections caused by fungus by administration of tafenoquine | Pharmaceuticals | 60 DEGREES PHARMACEUTICALS LLC |
| Sep 5, 2023 | 11,744,828 | Regimens of tafenoquine for prevention of malaria in malaria-naïve subjects | Pharmaceuticals | 60 DEGREES PHARMACEUTICALS LLC |
| Apr 25, 2023 | 11,633,391 | Methods for the treatment and prevention of lung infections caused by gram-positive bacteria, fungus, or virus by administration of tafenoquine | Pharmaceuticals | 60 DEGREES PHARMACEUTICALS LLC |
| Jan 11, 2022 | 11,219,616 | Dosing regimens of celgosivir for the treatment of dengue | Pharmaceuticals | 60 DEGREES PHARMACEUTICALS LLC |
| May 11, 2021 | 11,000,516 | Dosing regimens of celgosivir for the prevention of dengue | Pharmaceuticals | 60 DEGREES PHARMACEUTICALS LLC |
| Jan 12, 2021 | 10,888,558 | Regimens of tafenoquine for prevention of malaria in malaria-naive subjects | Pharmaceuticals | 60 DEGREES PHARMACEUTICALS LLC |
| Dec 31, 2019 | 10,517,854 | Dosing regiments of celgosivir for the treatment of dengue | Pharmaceuticals | 60 DEGREES PHARMACEUTICALS LLC |
| Jul 9, 2019 | 10,342,791 | Regimens of tafenoquine for prevention of malaria in malaria-naive subjects | Pharmaceuticals | 60 DEGREES PHARMACEUTICALS LLC |
| Sep 19, 2017 | 9,763,921 | Dosing regimens of celgosivir for the treatment of dengue | Pharmaceuticals | 60 DEGREES PHARMACEUTICALS LLC |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Mar 6, 2025 | 2025/0073222 | METHODS FOR THE TREATMENT AND PREVENTION OF NON-VIRAL TICK-BORNE DISEASES AND SYMPTOMS THEREOF | Pharmaceuticals | 60 DEGREES PHARMACEUTICALS LLC |
| Dec 12, 2024 | 2024/0408074 | METHODS FOR THE TREATMENT AND PREVENTION OF NON-VIRAL TICK-BORNE DISEASES AND SYMPTOMS THEREOF OF | Pharmaceuticals | 60 DEGREES PHARMACEUTICALS LLC |
| Nov 28, 2024 | 2024/0390359 | METHODS FOR THE TREATMENT AND PREVENTION OF NON-VIRAL TICK-BORNE DISEASES AND SYMPTOMS THEREOF | Pharmaceuticals | 60 DEGREES PHARMACEUTICALS LLC |
| Jul 11, 2024 | 2024/0226087 | METHODS FOR THE TREATMENT AND PREVENTION OF LUNG INFECTIONS CAUSED BY GRAM-POSITIVE BACTERIA, FUNGUS, OR VIRUS BY ADMINISTRATION OF TAFENOQUINE | Pharmaceuticals | 60 DEGREES PHARMACEUTICALS LLC |
| May 23, 2024 | 2024/0165099 | METHODS FOR THE TREATMENT AND PREVENTION OF DISEASES OR INFECTIONS WITH MCP-1 INVOLVEMENT BY ADMINISTRATION OF TAFENOQUINE | Pharmaceuticals | 60 DEGREES PHARMACEUTICALS LLC |
| Apr 25, 2024 | 2024/0131019 | METHODS FOR THE TREATMENT AND PREVENTION OF LUNG INFECTIONS CAUSED BY GRAM-POSITIVE BACTERIA, FUNGUS, OR VIRUS BY ADMINISTRATION OF TAFENOQUINE | Pharmaceuticals | 60 DEGREES PHARMACEUTICALS LLC |
| Mar 14, 2024 | 2024/0082233 | Regimens of Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects | Pharmaceuticals | 60 DEGREES PHARMACEUTICALS LLC |
| Jan 11, 2024 | 2024/0009176 | METHODS TO TREAT RESPIRATORY INFECTION UTILIZING CASTANOSPERMINE ANALOGS | Pharmaceuticals | 60 DEGREES PHARMACEUTICALS LLC |
| Jan 19, 2023 | 2023/0018428 | METHODS FOR THE TREATMENT AND PREVENTION OF LUNG INFECTIONS CAUSED BY FUNGUS BY ADMINISTRATION OF TAFENOQUINE | Pharmaceuticals | 60 DEGREES PHARMACEUTICALS LLC · patent 12,383,546 granted from it |
| Dec 8, 2022 | 2022/0387419 | METHODS FOR THE TREATMENT AND PREVENTION OF LUNG INFECTIONS CAUSED BY SARS-COV-2 VIRUS BY ADMINISTRATION OF TAFENOQUINE | Pharmaceuticals | 60 DEGREES PHARMACEUTICALS LLC |
What it applied for, 2024 to 2025: Pharmaceuticals 8.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.